Skip to main content
Premium Trial:

Request an Annual Quote

Incyte s Revenues Take a Dive, Losses Narrow in Q1

NEW YORK, May 4 (GenomeWeb News) - Incyte's revenues were almost cut in half, while its losses narrowed during Q1 of 2004, the company reported today.

 

Revenues for the quarter plummeted to $6.6 million, from $12.5 million during the same period last year. Incyte attributed this decrease to the discontinuation of its genomic data products.

 

R&D costs decreased to $26.2 million, down from $30.2 million during the first quarter of 2003.

 

Incyte's net loss decreased to $37.7 million, or $.52 per share, from $55.8 million, or $.81 per share, during the year-ago period.

 

As of March 31, Incyte had $500.7 million in cash, cash equivalents and marketable securities, compared to $293.8 million at the end of 2003. This increase results from the company's sale of convertible subordinated notes, which generated net proceeds of $242 million.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.